The Quantellect read.As of Nov 19, 2026, 3 active firms cover Bio-Rad Laboratories Inc: 1 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets are tightly clustered, $330.00 to $390.00, so the covering firms are broadly aligned. The average target of $350.00 sits 5% below the current $370.17. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.83 next quarter toward $9.91 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Neutral
Strong Buy00%
Buy133%
Neutral267%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$350.00
-5.4% downside
Average target across 3 active firms as of Nov 19, 2026 vs $370.17 current
Highest Target$390.00
Average Target$350.00
Lowest Target$330.00
Detailed analyst forecasts for BIO
Showing 1–5 of 5 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 1 of 3 active firms rate BIO a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BIO EPS & revenue forecast
EPS · NEXT QUARTER
$2.83
Range $2.83 – $2.83 · 1 analysts · +50% YoY
Next period, 1 analysts expect Bio-Rad Laboratories Inc to earn $2.83 a share (range $2.83 – $2.83), versus $1.89 a year earlier. Full-year consensus is $9.61, growing to $9.91 the year after.
REVENUE · NEXT QUARTER
$611.3M
Range $611.3M – $611.3M · 1 analysts · +3% YoY
Revenue is expected to reach $611.3M (range $611.3M – $611.3M), +3.2% year-over-year. Full-year consensus is $2.6B, rising to $2.6B next year.
Top analysts covering Bio-Rad Laboratories Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BIO.
#1
Conor McNamara
RBC Capital · Rank #254
Buy
$409.00+10.5% to target
Overall win rate
34%
+ Follow
#2
Patrick Donnelly
Citigroup · Rank #448
Neutral
$300.00-19.0% to target
Overall win rate
29%
+ Follow
#3
Brandon Couillard
Wells Fargo
Neutral
$290.00-21.7% to target
Coverage
—
+ Follow
#4
DL
Dan Leonard
RBC Capital
Buy
$390.00+5.4% to target
Coverage
—
+ Follow
#5
Daniel Grosslight
Citigroup
Neutral
$330.00-10.9% to target
Coverage
—
+ Follow
BIO stock forecast FAQ
What is BIO's average 12-month price target?+
The 3 active firms with a live target average $350.00 for Bio-Rad Laboratories Inc over the next 12 months, ranging from a $390.00 high to a $330.00 low, as of Nov 19, 2026.
Is BIO stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 3 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BIO?+
The Street-high target is $390.00 (RBC Capital), and the Street-low is $330.00 (Citigroup). The average of all 3 active-firm targets is $350.00.
How many active Wall Street firms cover BIO?+
3 active firms have a recognized rating on Bio-Rad Laboratories Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BIO?+
Among analysts who currently cover BIO, Conor McNamara of RBC Capital has the strongest overall Quantellect track record (Rank #254). Their current call is Buy with a $409.00 target.
What is Bio-Rad Laboratories Inc's projected EPS for next quarter?+
The consensus estimate is $2.83 per share (range $2.83 – $2.83) across 1 analysts. Full-year EPS is projected at $9.61, rising to $9.91 the following year.
How much revenue is Bio-Rad Laboratories Inc expected to report next quarter?+
Consensus revenue is $611.3M (range $611.3M – $611.3M). Full-year revenue is projected at $2.6B, growing to $2.6B next year.
Have analysts been upgrading or downgrading BIO lately?+
As of Nov 19, 2026, 1 of 3 active firms rate BIO a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.